Samil Pharmaceutical Co (000520) Fair Value & Analysis
Healthcare · KR · Market cap 155B KRW
Fair value as of: Jun 25, 2026
From 4 valuation models · updated 5 days ago
Share price −19.9% over the past month.
Price vs Fair Value (12 months)
12‑month range 6,500 KRW – 13,403 KRW · fair‑value band 21,185 KRW – 35,309 KRW · the 6,500 KRW price screens below the 28,247 KRW fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Samil Pharmaceutical Co (000520) currently trades at 6,500 KRW, while our model-based Fair Value estimate is 28,247 KRW — implying the stock looks roughly 334.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Samil Pharmaceutical Co generated revenue of 211B KRW at a net margin of -17.3%. Revenue grew 0.5% year over year. It earns a return on equity of -24.7%. Net debt stands at 156B KRW. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of pharmaceuticals in South Korea. It offers general medicines, including Tiersil Once, EYE2O mini eye drops, and Optagent ophthalmic drops; medical devices; secret spotpatch quasi-drugs, and roll away products. The company also provides specialty medicines, such as Hycell solutions; Curelen, Ocufridine, Ocumetholone, Ocucyclo, Ocuhomapine, Ocucarpine, Allerfen, Optanac, Forus, Eymox, Cifex, and Ocuracin ophthalmic drops; and Herpecid, Forus, and Ocurasin ophthalmic ointments. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Samil Pharmaceutical Co reported revenue of 210B KRW in FY2025 versus 134B KRW in FY2021, a compound +11.9%/yr. Reported net income was −34.7B KRW in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Samil Pharmaceutical Co (000520) undervalued?
What is the fair value of 000520?
What is the quality score of 000520?
What is the revenue of Samil Pharmaceutical Co (000520)?
What is the net profit margin of 000520?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.